Arterial Thrombosis

Risk for myeloproliferative neoplasms among U.S. veterans increased significantly over time, according to retrospective study results.

The American College of Chest Physicians recently issued new clinical guidance on antithrombotic therapy for arterial thrombosis and thromboembolism in patients with COVID-19.

Data from a systematic review suggest that adults with isolated pulmonary embolism, the majority of whom are women, are more likely to have prevalent CVD and are at increased risk for arterial thrombosis.

AngioDynamics announced it received an FDA clearance of an expanded indication for its atherectomy system to include arterial thrombectomy.

Atorvastatin vs. placebo to prevent death and thrombosis in patients COVID-19 in the ICU.

Rivaroxaban (Xarelto, Janssen/Bayer)-based therapeutic anticoagulation vs. standard of care in patients with COVID-19.

Atorvastatin therapy did not reduce risk for venous or arterial thrombosis or all-cause death among patients with COVID-19 admitted to the ICU compared with placebo, according to data from the INSPIRATION-S study.

A rivaroxaban-based anticoagulation strategy did not improve outcomes and increased bleeding in patients hospitalized with COVID-19 compared with standard hospital prophylaxis, according to data from the ACTION trial.

Patients with cancer appeared at increased risk for arterial thromboembolism and mortality within 1 year of cancer diagnosis compared with the general population, according to an epidemiological analysis published in JACC: CardioOncology.